Press Releases

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with <i>BRCA2</i> mutations that may increase or decrease their risk of developing breast cancer.

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the <i>British Medical Journal</i>.

Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the <i>New England Journal of Medicine</i>.

Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010.

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.

Physician-scientist Boris C. Bastian joined Memorial Sloan Kettering as Attending Physician and Chair of the Department of Pathology on April 1.

A unique collaboration among physician-scientists at Memorial Sloan Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. The study, published in the journal <I>Cancer Cell</I>, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.